Akzo Nobel's Nobilon and BioDiem sign influenza vaccine tie-up
The agreement gives Nobilon access to BioDiem's technological expertise in influenza vaccines and will enable the development of a new generation of flu vaccines based on cell-culture technology that offer a patient friendly method of administration. The vaccine is not expected on the market until around 2010.
Akzo Nobel Board Member, Toon Wilderbeek commented: "The agreement between ourselves and BioDiem is a synergistic move that builds on our group's expertise in vaccine development and production." Speaking about the tie-up between the two companies, Nobilon Director Bram van Dijck, said: "The BioDiem live attenuated influenza vaccine technology has a number of important features that we can capitalize on to develop a better flu vaccine that will address the need for broader protection against influenza and ensure a more flexible and efficient supply." Tom Williams, BioDiem's Managing Director, added: "We are delighted to have Nobilon as a partner for our novel flu vaccine as the fit is excellent and provides both companies with a strategic position in a high volume market which is growing strongly."
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Cell culture technology
Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.
Topic world Cell culture technology
Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.